Vinay Prasad has reversed his abrupt departure and is set to resume leadership at the FDA's Center for Biologics Evaluation and Research (CBER), responsible for vaccine and gene therapy oversight. This development follows escalating tensions linked to a gene therapy product for Duchenne muscular dystrophy by Sarepta Therapeutics and a politically charged public campaign. Health and Human Services confirmed the FDA's request for Prasad's return, reflecting upheaval within regulatory leadership in a critical biomedical sector.